Keysight Automated Test Solution Validates Fortinet's SSL Deep Inspection Performance and Network Security Efficacy
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250805646957/en/
Keysight's BreakingPoint QuickTest simplifies application performance and security effectiveness assessments with predefined test configurations and self-stabilizing, goal-seeking algorithms to deliver relevant, up-to-date test scenarios with real-world applications.
Enterprise networks and systems face a constant onslaught of cyber-attacks, including malware, vulnerabilities, and evasions. These attacks are taking a toll, as 67% of enterprises report suffering a breach in the past two years, while breach-related lawsuits have risen 500% in the last four years.
Fortinet developed the FortiGate 700G series NGFW to help protect enterprise edge and distributed enterprise networks from these ever-increasing cybersecurity threats, while continuing to process legitimate customer-driven traffic that is vital to their core business. The FortiGate 700G is powered by Fortinet's proprietary Network Processor 7 (NP7), Security Processor 5 (SP5) ASIC, and FortiOS, Fortinet's unified operating system. Requiring an application and security test solution that delivers real-world network traffic performance, relevant and reliable security assessment, repeatable results, and fast time-to-insight, Fortinet turned to Keysight's BreakingPoint QuickTest network applications and security test tool.
Using BreakingPoint QuickTest, Fortinet validated the network performance and cybersecurity capabilities of the FortiGate 700G NGFW using:
Simplified Test Setup and Execution: Pre-defined performance and security assessment suites, along with easy, click-to-configure network configuration, allow users to set up complex tests in minutes.
Reduced Test Durations: Self-stabilizing, goal-seeking algorithms accelerate the test process and shorten the overall time-to-insight.
Scalable HTTP and HTTPS Traffic Generation: Supports all RFC 9411 tests used by NetSecOPEN, an industry consortium that develops open standards for network security testing. This includes the 7.7 HTTPS throughput test, allowing Fortinet to quickly assess that the FortiGate 700G NGFW's SSL Deep Inspection engine can support up to 14 Gbps of inspected HTTPS traffic.
NetSecOPEN Security Efficacy Tests: BreakingPoint QuickTest supports the full suite of NetSecOPEN security efficacy tests, including malware, vulnerabilities, and evasions. This ensures the FortiGate 700G capabilities are validated with relevant, repeatable, and widely accepted industry standard test methodologies and content.
Robust Reporting and Real-time Metrics: Live test feedback and clear, actionable reports showed that the FortiGate 700G successfully blocked 3,838 of the 3,930 malware samples, 1,708 of the 1,711 CVE threats, and stopped 100% of evasions, earning a grade 'A' across all security tests.
Nirav Shah, Senior Vice President, Products and Solutions, Fortinet, said: 'The FortiGate 700G series next-generation firewall combines cutting-edge artificial intelligence and machine learning with the port density and application throughput enterprises need, delivering comprehensive threat protection at any scale. Keysight's intuitive BreakingPoint QuickTest application and security test tool made our validation process easy. It provided clear and definitive results that the FortiGate 700G series NGFW equips organizations with the performance and advanced network security capabilities required to stay ahead of current and emerging cyberthreats.'
Ram Periakaruppan, Vice President and General Manager, Keysight Network Test and Security Solutions, said: 'The landscape of cyber threats is constantly evolving, so enterprises must be vigilant in adapting their network defenses, while also continuing to meet their business objectives. Keysight's network application and security test solutions help alleviate the pressure these demands place on network equipment manufacturers by providing an easy-to-use package with pre-defined performance and security tests, innovative goal-seeking algorithms, and continuously updated benchmarking content, ensuring solutions meet rigorous industry requirements.'
Resources
About Keysight Technologies
At Keysight (NYSE: KEYS), we inspire and empower innovators to bring world-changing technologies to life. As an S&P 500 company, we're delivering market-leading design, emulation, and test solutions to help engineers develop and deploy faster, with less risk, throughout the entire product lifecycle. We're a global innovation partner enabling customers in communications, industrial automation, aerospace and defense, automotive, semiconductor, and general electronics markets to accelerate innovation to connect and secure the world. Learn more at Keysight Newsroom and www.keysight.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
29 minutes ago
- CTV News
U.S. to initially impose ‘small tariff' on pharma imports, Trump says
President Donald Trump talks to reporters on the South Lawn of the White House before he boards Marine One en route to Joint Base Andrews, Md., Friday, Aug. 1, 2025, in Washington. (AP Photo/Mark Schiefelbein) WASHINGTON — U.S. President Donald Trump said on Tuesday that the United States would initially place a 'small tariff' on pharmaceutical imports before hiking it to 150 per cent within 18 months and eventually to 250 per cent in an effort to boost domestic production. 'In one year, one and a half years maximum, it's going to go to 150 per cent and then it's going to go to 250 per cent because we want pharmaceuticals made in our country,' Trump told CNBC in an interview. He did not specify the initial tariff rate on pharmaceuticals. Trump said last month that pharmaceutical tariffs could reach as high as 200 per cent. He said in February that sectoral tariffs on pharmaceuticals and semiconductor chips would start at '25 per cent or higher,' rising substantially over the course of a year. Trump said on Tuesday that he plans to announce tariffs on semiconductors and chips in the 'next week or so,' but gave no further details. The United States has been conducting a national security review of the pharmaceutical sector, and the industry has been preparing for possible sector-specific tariffs. The administration has not announced when the results of that probe will be released. Several drugmakers have pledged multibillion-dollar investments in U.S. manufacturing as Trump threatens import tariffs, with AstraZeneca recently committing US$50 billion to expand its American operations. PhRMA, the main lobbying group for the industry, did not immediately respond to a request for comment. A framework agreement between the United States and the EU sets out that tariffs on pharmaceuticals and semiconductors are currently zero, but if the United States raises tariffs following its import investigation, they will be capped at 15 per cent. --- Reporting by Patrick Wingrove in New York, Andrea Shalal in Washington and Bhargav Acharya in Toronto; Editing by Doina Chiacu and Mark Porter
Globe and Mail
29 minutes ago
- Globe and Mail
UBS to Pay $300M to Settle Credit Suisse Mortgage Securities Lawsuit
UBS Group AG UBS has agreed to pay $300 million to the United States Department of Justice (DOJ) to resolve a legacy matter related to the mis-selling of mortgage-linked investments by Credit Suisse in the United States. On Aug. 1, 2025, Credit Suisse Securities (USA) LLC agreed to settle all Credit Suisse's outstanding consumer relief obligations under the 2017 settlement for its residential mortgage-backed securities (RMBS) business. History of the UBS Lawsuit In January 2017, Credit Suisse reached a $5.28 billion settlement over its role in selling residential mortgage-backed securities between 2005 and 2007. The agreement required the bank to pay $2.48 billion as a civil penalty to the U.S. government, along with $2.8 billion in relief measures such as loan modifications for struggling homeowners, debt forgiveness and funding for affordable housing initiatives. The 2017 settlement was part of a broader initiative by the U.S. authorities to hold major banks accountable for their involvement in the 2007–2008 financial crisis. The DOJ raised allegations that Credit Suisse knowingly acquired and securitized low-quality mortgage loans while misleading investors about the associated risks of these securities. In the years leading up to the crisis, many large banks engaged in misconduct related to RMBS. The DOJ ultimately collected roughly $36 billion in civil penalties from 18 financial institutions for RMBS-related fraud during that period. UBS resolved its own RMBS case with the DOJ in August 2023, agreeing to pay about $1.44 billion in a civil penalty, roughly four months after it acquired Credit Suisse in a $3.25 billion government-orchestrated deal. Other Regulatory Probes Faced by UBS In May 2025, UBS agreed to pay $511 million to resolve a tax probe by the U.S. DOJ against Credit Suisse for preparing false income tax returns and tax evasion. The two-year investigation by the DOJ, initiated before UBS acquired Credit Suisse, found that Credit Suisse aided and assisted in tax evasion through its 475 offshore accounts to prepare false tax returns to conceal more than $4 billion from the US Internal Revenue Service (IRS). The DOJ reported that most of this misconduct occurred between 2014 and June 2023. Thus, an increase in claims against the company and regulatory fines over Credit Suisse's dealings is expected to increase litigation provisions in the near term. Over the past six months, UBS Group shares have gained 11.9% compared with the industry 's 17.6% rise. UBS currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Litigations Faced by Other Finance Firms Last month, CNBC reported that Robinhood Markets, Inc. HOOD is under investigation by Lithuania's central bank, its lead regulator in the European Union (EU), regarding its newly launched tokenized equity products. The scrutiny follows Robinhood's recent launch of its Stock Tokens product across the EU, aimed at offering blockchain-based tokenized access to shares, including those of private firms. The offering sparked immediate questions from OpenAI, which openly distanced itself from HOOD's product. Robinhood defended the tokens by highlighting that they are backed by ownership interests designed to provide investors with indirect exposure to private markets. Nonetheless, regulators remain wary, specifically regarding the transparency and legality of how these digital instruments are offered to retail investors. In June, in a ruling, Anthony Trenga, U.S. District Judge in Alexandria, VA, announced that Capital One COF will have to face a lawsuit by social media creators who claim that the bank's free browser extension deprived them of commissions on sales generated through their content. According to the creators, the Capital One Shopping browser extension, which has more than 10 million users, is used to discover discounts. It erroneously reflected Capital One as the source of referral traffic at checkout, making it appear as if consumers had clicked the bank's referral links before making purchases. The creators alleged that this enabled Capital One to collect millions of dollars in commissions that rightfully belonged to bloggers, influencers, YouTubers and other content creators. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> UBS Group AG (UBS): Free Stock Analysis Report Robinhood Markets, Inc. (HOOD): Free Stock Analysis Report
Globe and Mail
29 minutes ago
- Globe and Mail
These 3 CEOs Just Bought the Dip
Investors closely monitor insider buys, as they can give hints surrounding the long-term picture. But it's critical to note that insiders have a longer holding period than most, and many strict rules apply to their transactions. Recently, CEOs of several companies – MSCI (MSCI), Charter Communications (CHTR), and Healthpeak Properties (DOC) – have made splashes, acquiring shares. Let's take a closer look at the transactions for those interested in trading like the insiders. MSCI CEO Buys Millions Worth MSCI provides investment decision support tools, including indexes; portfolio construction and risk management products and services; Environmental, Social and Governance (ESG) research and ratings; and real estate research, reporting and benchmarking offerings. The stock is a Zacks Rank #2 (Buy) thanks to positive EPS revisions, with analysts taking expectations higher across the board over recent months. Henry Fernandez, CEO, recently has purchased roughly 12.5k MSCI shares, with the total transaction totaling roughly $6.7 million. As shown below, the purchase aligned with a dip in MSCI shares, reflective of confidence in the positive EPS and broader long-term outlook. CHTR CEO Dives In Charter Communications is the second-largest cable operator in the United States and a leading broadband communications company providing video, internet, and voice services. CEO Christopher Winfrey recently purchased roughly 3.6k CHTR shares at a total transaction value of just over $1 million. As shown below, the purchase coincided with a plunge in CHTR shares, with the CEO scooping up shares at a discounted level. X Still, analysts have lowered their EPS outlooks across the board, likely reflective of further short-term pain ahead. Positive EPS revisions would be key for a positive turnaround in sentiment, with the CEO's long holding horizon an obvious advantage here. Healthpeak CEO Buys Healthpeak Properties is a REIT in the United States that acquires, develops, manages, sells, and leases a diverse portfolio of healthcare real estate-related properties. Insiders have regularly bought on share weakness in 2025, as we can see in the green arrows in the chart below. X CEO Scott Brinker recently swooped in and purchased roughly 6k DOC shares at a total transaction value of roughly $100k. He now owns more than 210k shares overall. The stock's weak performance has been partly driven by negative earnings estimate revisions, currently a Zacks Rank #4 (Sell). The purchases here are relatively unsurprising, given the CEO's long-term horizon and the discount that shares are currently displaying. However, near-term performance can be expected to remain soft given the cloudy EPS outlook. Bottom Line Many investors closely monitor insider buys, looking to receive insights into the longer-term picture. The transactions shouldn't be relied on for near-term performance, as insiders' holding periods are longer than most, and many strict rules apply. Rather, investors can see insider buys as an overall net positive concerning the longer-term outlook. All large-cap stocks above – Healthpeak Properties DOC, MSCI MSCI, and Charter Communications CHTR – have seen recent insider activity. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> MSCI Inc (MSCI): Free Stock Analysis Report
